InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: None

Friday, 12/02/2016 2:44:24 PM

Friday, December 02, 2016 2:44:24 PM

Post# of 345792
Dr Wayne C Koff knows of PS Targeting and what will glycoproteins mean for flipped PS targeting?

Looks like Peregrine should have lots to tell us over the next few months and Sean Parker continues to act as the disrupter that Big Pharma will soon realize that one of them will step up and try and pick up Perevrine Pharmaceuticals

Burton DR, Mascola JR: Antibody response to envelope
glycoproteins in HIV-1 infection. Nat Immunol 2015, 16:571-576. This paper summarized the recent advances in isolation of many HIV- specific broadly neutralizing antibodies and discusses how they are being used to guide HIV vaccine development.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News